[Editors' note: This story was updated Nov. 21 to clarify that FDA's email to stakeholders did not explicitly state that the agency is delaying the final LDT guidance.]
FDA Puts Lab-Developed Test Oversight Plans On Hold
After years of wrangling over lab-developed test regulations with laboratory lobbyists, FDA has put its plans to finalize a guidance that lays out its oversight framework for LDTs on hold as a new Congress and a new deregulation-focused president-elect is set to take the helm.
